Research news // 30th November 2018
The 60th American Society of Haematology Annual Meeting (ASH) will be taking place this weekend (1-4 December) in San Diego, California. Our Director of Research Simon Ridley and Director of Healthcare Advocacy Services Ira Laketic-Ljubojevic will be attending to report back the latest myeloma research.
What is ASH?
ASH is one of the biggest haematology conferences in the world with more than 25,000 attendees. Haematology is the branch of medicine that covers all blood disorders including haemophilia, sickle cell anaemia, lymphoma and myeloma.
Why is it important?
Attendees will come from around the world to learn about the latest research covering more than 5,000 topics. These topics will include studies on why myeloma happens, why it differs between individuals and how we best treat it.
Some of the research funded by Myeloma UK, the MUK five and MUK seven clinical trials, will be presented at the conference.
Kwee Yong from University College London will share results from MUK five. She will explain how different subtypes of myeloma respond to treatment with carfilzomib and bortezomib based triplets and how maintenance treatment with carfilzomib impacts the response to treatment.
Preliminary results from MUK seven will also be presented. James Croft from the Royal Marsden Hospital will share how cyclophosphamide, pomalidomide and dexamethasone compare to pomalidomide and dexamethasone in relapsed and refractory myeloma patients.
Other exciting topics to be discussed will include early results from small trials exploring the use of CAR-T therapies in myeloma and results from large clinical trials evaluating the effect of new daratumumab and carfilzomib based combination treatments and the benefit of continuous versus dose adjusted treatments for elderly patients.
Look out for more news from ASH on twitter, LinkedIn or Facebook.